Study facts at a glance
Main trial: A randomized, double-blind study enrolled 37 volunteers for 12 weeks: 19 received benzoyl peroxide gel and 18 received chloroxylenol plus salicylic acid cream. Source 1
Tested formulations: The comparison was 5% benzoyl peroxide gel versus 0.5% chloroxylenol plus 2% salicylic acid cream, not salicylic acid alone. Source 1
Lesion reductions: At week 12, inflammatory lesions fell 60% versus 62%, and noninflammatory lesions fell 54% versus 56%, for benzoyl peroxide and the combination, respectively. Source 1
Statistical boundary: The abstract reports no statistically significant between-group lesion-count difference, but supplies no confidence intervals or formal equivalence analysis. Source 1
Safety boundary: Redness and photosensitivity were reported less often with the combination at week 12, but the abstract does not provide event frequencies from which to calculate absolute risks. Source 1
What the 37-person trial actually compared
The main study randomly assigned 37 volunteers to one of two topical acne treatments. Nineteen received 5% benzoyl peroxide gel; 18 received a cream containing 0.5% chloroxylenol and 2% salicylic acid, identified in the abstract as Nisal cream. The study was described as double-blind, meaning treatment identities were concealed within the trial, although the abstract does not explain the masking procedures.
Participants applied their assigned treatment to the entire face twice daily for 12 weeks. These details identify the research exposure, not a recommended schedule for another product. Investigators performed clinical evaluations and lesion counts at baseline and at weeks 3, 6, 9, and 12. Repeated visits allowed observation over time, although the abstract provides numerical lesion reductions only for the final visit.
The accessible report does not give participant ages, a detailed baseline severity distribution, baseline lesion counts, or a clearly designated single primary endpoint. It also does not identify a sponsor. Consequently, its clearest contribution is a comparison of two specific regimens over three months—not a complete description of which patients would obtain the same results.
Read the underlying chart data: download CSV or download the source-labeled chart.
Reading the lesion reductions without inflating the result
The investigators distinguished inflammatory lesions, such as papules and pustules, from noninflammatory lesions, or comedones. Comedones include blackheads and whiteheads. At week 12, the benzoyl peroxide group had reported reductions of 60% in inflammatory lesions and 54% in noninflammatory lesions. Corresponding reductions with the combination cream were 62% and 56%.
The numerical advantage was therefore 2 percentage points for each lesion category. That is not a finding that the combination cleared an additional 2% of participants, nor that 62% of people became clear. The percentages describe changes in lesion counts, not the fraction of participants reaching a clinical success threshold. The abstract does not report such a threshold.
For a simplified illustration, a 60% reduction from 20 lesions would leave eight; a 62% reduction from the same starting count would leave 7.6 as a group average. This is arithmetic, not reconstructed participant data. Actual starting counts and individual responses are unavailable, so these percentages cannot tell us how many lesions a particular person would lose.
Reported week-12 lesion-count changes in the main trial
| Outcome | 5% benzoyl peroxide gel | 0.5% chloroxylenol + 2% salicylic acid cream |
|---|---|---|
| Assigned participants | 19 | 18 |
| Inflammatory lesion reduction | 60% | 62% |
| Noninflammatory lesion reduction | 54% | 56% |
| Between-group lesion comparison | No statistically significant difference reported | No statistically significant difference reported |
Similar numbers are not proof of equivalence
The abstract concludes that the combination was as effective as benzoyl peroxide. A more cautious interpretation is that this small study did not detect a statistically significant difference in the reported lesion outcomes. Those statements are not interchangeable. Failure to establish a difference does not establish that any possible difference is too small to matter.
Formal equivalence or noninferiority testing ordinarily needs a predefined acceptable margin and sufficiently precise estimates. Neither an equivalence margin nor confidence intervals are available in this abstract. Without those intervals, readers cannot see the range of treatment differences compatible with the observations. With only 18 and 19 participants per arm, precision is an important unresolved issue.
The active-comparator design also answers a different question from a vehicle-controlled trial. Both groups improved while receiving active treatment, but the study does not separately estimate the effect of either formulation against its own inactive base. Randomization strengthens the between-treatment comparison; it does not supply missing comparisons or establish that the observed 2-percentage-point gaps represent real advantages.
The cream tested more than salicylic acid
The combination arm contained two active ingredients, while the comparator contained benzoyl peroxide. It also used a cream rather than a gel. The trial therefore compared complete formulations, not isolated ingredients. Any difference could reflect the active ingredients, the vehicle, their interaction, or how participants tolerated and used the products.
The abstract describes a slightly stronger keratolytic effect with the combination during follow-up. Keratolytic activity concerns loosening or shedding surface skin material, a concept relevant to blockage. However, the accessible report does not provide a separate quantitative measure that would allow readers to assign that effect specifically to salicylic acid. A salicylic-acid-only arm and suitable formulation controls would address a different, more ingredient-specific question.
This distinction matters when moving from research to product comparisons. A matching 2% concentration does not recreate the studied cream. The guide to evaluating pore-treatment claims offers a useful framework: first identify the whole formulation and the outcome actually studied. Similar ingredient language is not a bridge to demonstrated clinical equivalence.
The tolerability finding lacks absolute event rates
At week 12, the combination group had significantly fewer adverse effects involving erythema, meaning redness, and photosensitivity. The reported P values were 0.0002 for erythema and 0.05 for photosensitivity. These are reported tolerability comparisons, but the abstract does not give the number of affected participants, the severity distribution, or the absolute difference between groups.
A P value is not an adverse-event percentage. The erythema result does not mean that redness affected 0.02% of users, and the photosensitivity result does not mean a 5% risk. Such values describe statistical evidence under a comparison model; without event counts and denominators, they cannot establish how common either problem was.
Nor does a favorable comparison for two reactions demonstrate that the cream caused no irritation or allergy. A 37-person trial is poorly suited to characterizing uncommon events, and the abstract does not provide a full adverse-event inventory. The defensible conclusion is a relative tolerability signal for the specified outcomes at the final visit, not a blanket safety claim.
An addition study found a different benefit–dryness balance
A separate randomized study enrolled 49 patients with mild to moderate facial acne for 12 weeks. This prospective, single-blind comparison tested adding salicylic acid to clindamycin phosphate plus benzoyl peroxide versus the clindamycin–benzoyl peroxide regimen alone. It was not a replication of the chloroxylenol cream trial and did not test salicylic acid as a stand-alone treatment.
The abstract reports better reductions in inflammatory and total lesion counts throughout study weeks, and in noninflammatory lesions beyond two weeks, with the added salicylic acid treatment. Patient- and investigator-rated global improvement also favored the addition at the end. But numerical effect sizes, confidence intervals, and the salicylic acid concentration are absent, preventing a quantitative comparison with the 37-person trial.
The added treatment also produced more frequent mild to moderate transient dryness. Both regimens reduced hydration in the stratum corneum, the outer skin layer; measured sebum values decreased with the salicylic-acid-containing regimen. These findings challenge a simple claim that salicylic combinations are always gentler. The antibiotic-containing background treatment also makes this a distinct clinical question, not a do-it-yourself combination recipe.
The shorter split-face study tested another formulation
A third study compared modified, supramolecular 2% salicylic acid cream with benzoyl peroxide plus adapalene on opposite sides of the same face. It was randomized, open-label, and conducted at one center over 28 days. Thirty-one participants completed it; they were not 62 independent patients. The abstract does not supply the initial enrollment denominator or explain attrition.
At day 28, inflammatory lesions decreased 47.9% versus 49.8%, noninflammatory lesions 43.1% versus 42.7%, and total lesions 44.1% versus 45.6%, for supramolecular salicylic acid and the comparator, respectively. Reported differences were not statistically significant. The title and methods identify 0.1% adapalene with 5% benzoyl peroxide, but the objectives also state 0.01% adapalene. That inconsistency remains unresolved in the accessible abstract.
The separate analysis of the split-face study explores its skin measurements and design. Its short duration, modified formulation, and within-person comparison prevent simple pooling with the 12-week cream trial. Neither nonsignificant lesion comparisons nor nonsignificant differences in hydration and water loss establish formal equivalence or absence of irritation.
Three studies answer different salicylic acid questions
| Study design | Comparison and duration | Main interpretive boundary |
|---|---|---|
| 37 volunteers; randomized, double-blind | Chloroxylenol–salicylic acid cream versus benzoyl peroxide gel; 12 weeks | Two active ingredients and different vehicles prevent isolating salicylic acid |
| 49 enrolled; randomized, single-blind | Salicylic acid added to clindamycin–benzoyl peroxide versus background regimen; 12 weeks | Benefit favored addition, but effect sizes were unavailable and dryness was more frequent |
| 31 completers; randomized, open-label, split-face | Supramolecular salicylic acid versus benzoyl peroxide–adapalene; 28 days | Modified formulation, short follow-up, and unresolved adapalene concentration discrepancy |
Fewer comedones do not establish smaller pores
The main trial counted acne lesions. It did not report measurements of pore diameter, permanent pore-size change, acne scars, or the proportion of participants whose skin became completely clear. A reduction in comedones supports a statement about fewer counted blackheads and whiteheads, not every appearance claim commonly attached to a pore-clearing product.
The distinction is practical rather than semantic. Someone assessing a product for visible texture may care about an outcome that investigators never measured. The blackheads and visible pores guide separates those concerns, while the pore-size explainer examines why removing a blockage and changing a pore's appearance are different endpoints.
FDA's cosmetic BHA discussion identifies salicylic acid with exfoliation, but it does not supply a precise pore-shrinkage benefit. Likewise, the acne monograph addresses acne lesions, blackheads, and whiteheads rather than permanent pore closure. Interpretation: the best-supported claim here stays close to lesion counting; broader cosmetic promises need their own direct measurements.
FDA context adds boundaries, not product approval
FDA's topical acne monograph lists salicylic acid at 0.5–2% and benzoyl peroxide at 2.5–10%. Those concentration ranges are only part of the applicable conditions. Matching a listed ingredient strength does not establish compliance with every condition, constitute individual product approval, or validate the chloroxylenol combination through a regulatory shortcut.
The monograph warns that combining topical acne medicines may increase dryness and irritation. Separately, FDA has warned about rare serious hypersensitivity reactions involving some products containing salicylic acid or benzoyl peroxide. The responsible ingredient was not established: active ingredients, inactive ingredients, or both could have contributed. This differs from ordinary localized dryness or stinging.
FDA advises stopping the product and seeking emergency care for throat tightness, breathing difficulty, faintness, or swelling of the eyes, face, lips, or tongue. Historical spontaneous reports cannot provide a user-level incidence without an exposure denominator. Small-area sensitivity testing also cannot guarantee that a later reaction will not occur. Product labeling remains essential even when an ingredient has a familiar name.
What evidence would make the comparison more useful
A stronger follow-up study would report baseline lesion burdens, participant characteristics, retention, adherence, prespecified endpoints, and confidence intervals. A larger sample could distinguish modest differences more precisely. Longer observation would help establish whether improvements persist and whether tolerability changes after the initial treatment period; the present abstract does not answer those questions.
Ingredient-specific conclusions would require additional comparison arms, while a pore-appearance claim would require a defined pore measurement rather than acne counts alone. Patient-reported outcomes could also clarify whether numerical changes translate into a noticeable benefit. These are different evidence gaps, so simply repeating a small active-comparator trial would not resolve all of them.
Editorial interpretation: when considering a service or subscription, documentary terms deserve a separate review from efficacy claims. The CoreAge Rx review and Likeness Rx review can be used to check what is documented about an offer and its renewal terms. These links do not imply that either provider supplies the studied cream, delivers condition-specific outcomes, or inherits the trial's results.
Questions about the evidence
Did the main trial prove that salicylic acid works as well as benzoyl peroxide?
It found no statistically significant lesion-count difference between a chloroxylenol–salicylic acid cream and benzoyl peroxide gel. That is narrower than proving equivalence, and it does not isolate salicylic acid. Confidence intervals and a predefined equivalence margin were not available in the abstract.
Does a 62% reduction mean that 62% of participants were acne-free?
No. The reported 62% figure concerns the reduction in inflammatory lesion counts in the combination group. It is not a clearance rate or the percentage of participants meeting a treatment-success definition. Individual responses and complete-clearance outcomes were not supplied.
Was the salicylic acid combination less irritating?
The main trial reported fewer erythema and photosensitivity events at week 12, but no absolute event frequencies. A different salicylic acid addition study found more transient dryness. Tolerability therefore depends on the tested formulation and regimen, not just whether salicylic acid appears among the ingredients.
Can the findings be applied to a 2% BHA cosmetic or cleanser?
Not automatically. The main trial tested a particular combination cream applied to the face, not every 2% cosmetic, rinse-off cleanser, compounded preparation, or other delivery form. The modified supramolecular preparation in the split-face study was also formulation-specific. Matching concentration alone does not establish matching exposure or outcomes.
What would show that the treatment improves visible pores?
A study would need a defined, reproducible pore-appearance endpoint and an appropriate comparison over a relevant follow-up period. Counting fewer blackheads or whiteheads is useful acne evidence, but it does not by itself measure pore diameter, permanent structural change, or the appearance of acne scars.
What this evidence supports
The 37-person trial supports a limited but useful conclusion: a specific chloroxylenol–salicylic acid cream produced substantial reported lesion-count reductions over 12 weeks, numerically close to benzoyl peroxide gel, with favorable final-visit findings for redness and photosensitivity. It does not establish ingredient-level equivalence, quantify absolute adverse-event risks, or demonstrate pore shrinkage. The other trials broaden the research context while showing why formulation, comparator, duration, and dryness outcomes must remain attached to each result.
Research access and limitations
Clinical analysis is based on indexed primary report abstracts, alongside official FDA materials. Full trial protocols, supplements, detailed statistical methods, funding disclosures, and complete adverse-event tables were not available in the accessed clinical evidence. The supramolecular study abstract contains an unresolved adapalene concentration discrepancy.